Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia
Status:
Completed
Trial end date:
2021-02-10
Target enrollment:
Participant gender:
Summary
The innovative drug Treamid is planned for use in the rehabilitation of patients after
COVID-19 pneumonia in a pilot, multicenter, randomized, double-blind, placebo-controlled
Phase II clinical study to assess the efficacy and safety of Treamid, tablets, 50 mg in
patients with fibrotic changes in the lungs after COVID-19 pneumonia during a 28-day
treatment.
The primary objective of the study is to demonstrate the efficacy of Treamid tablet, 50 mg in
change in forced vital capacity (FVC) and/or diffusing capacity of lung for carbon monoxide
(DLCO) at Week 4.
The secondary objective of the study is to evaluate the safety of Treamid tablet, 50 mg and
pharmacokinetics (PK).